PDS Biotechnology (PDSB) Stock Price, News & Analysis

Company Overview

PDS Biotechnology Group, Inc. is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform. The company’s research initiatives include both off‐the‐shelf vaccines targeting shared tumor antigens and personalized approaches that present patient‐specific neoantigens. By integrating novel adjuvant technology with established cancer targets, PDS Biotechnology aims to generate durable T-cell responses and improve clinical outcomes in multiple solid tumor indications.

Founded in 2007 and headquartered in San Diego, California, PDS Biotechnology conducts its research, translational studies, and early clinical development across facilities in the United States. The company partners with academic centers and biopharmaceutical organizations to advance its product candidates through global clinical trials. Under the leadership of CEO Bruce D. Montgomery and an experienced management team, PDS Biotechnology is dedicated to translating its platform innovations into next-generation immunotherapies for patients with cancer and chronic viral infections.

Key Stats

• Today's Range: $0.26 to $0.45
• 50-Day Range: $0.20 to $0.84
• 52-Week Range: $0.20 to $1.55
• Volume: 78.42 million shs
• Average Volume: 27.52 million shs
• Market Capitalization: $22.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Hold

PDS Biotechnology Stock Analysis - MarketRank™

PDS Biotechnology scored higher than 56% of companies evaluated by MarketBeat, and ranked 455th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Hold

Consensus Rating

PDS Biotechnology has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

PDS Biotechnology has a consensus price target of $9.00, representing about 2,155.1% upside from its current price of $0.40.

Amount of Analyst Coverage

PDS Biotechnology has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PDS Biotechnology are expected to grow in the coming year, from ($0.49) to ($0.30) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PDS Biotechnology is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PDS Biotechnology is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PDS Biotechnology has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.58% of the float of PDS Biotechnology has been sold short.

Short Interest Ratio / Days to Cover

PDS Biotechnology has a short interest ratio ("days to cover") of 1.44, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PDS Biotechnology has recently increased by 24.05%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PDS Biotechnology does not currently pay a dividend.

Dividend Growth

PDS Biotechnology does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.47

News Sentiment

PDS Biotechnology has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for PDS Biotechnology this week, compared to 2 articles on an average week.

Search Interest

6 people have searched for PDSB on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

11 people have added PDS Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 267% compared to the previous 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PDS Biotechnology insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.40% of the stock of PDS Biotechnology is held by insiders.

Percentage Held by Institutions

26.84% of the stock of PDS Biotechnology is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/14/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:PDSB
• CIK: 1472091
• Web: www.pdsbiotech.com
• Phone: (800) 208-3343
• Fax: 908-790-1212
• Employees: 20
• Year Founded: 2005

Price Target and Rating

• Average Price Target for PDS Biotechnology: $9.00
• High Price Target: $15.00
• Low Price Target: $3.00
• Potential Upside/Downside: +2,155.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.64)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$34.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -708.18%
• Return on Assets: -136.50%

Debt

• Debt-to-Equity Ratio: 2.73
• Current Ratio: 0.57
• Quick Ratio: 0.57

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 2.22

Miscellaneous

• Outstanding Shares: 55,971,000
• Free Float: 51,269,000
• Market Cap: $22.34 million
• Optionable: Optionable
• Beta: 1.46